| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 03/15/2021 | Viela Bio, Inc. | VIE | Other | Common Stock | 14.7M | $53.00 | $776.5M | See Footnote | 03/15/2021 |
| 12/19/2019 | Aevi Genomic Medicine, Inc. | CERC | Purchase | Common Stock | 12.9M | $0.00 | $0 | See footnote | 12/19/2019 |
| 10/07/2019 | Viela Bio, Inc. | VIE | Conversion | Series A-1 Preferred Stock | 14.2M | $0.00 | $0 | See footnote | 10/07/2019 |
| 10/07/2019 | Viela Bio, Inc. | VIE | Purchase | Common Stock | 425k | $19.00 | $8.1M | See footnote | 10/07/2019 |
| 10/07/2019 | Viela Bio, Inc. | VIE | Conversion | Common Stock | 14.2M | $0.00 | $0 | See footnote | 10/07/2019 |
| 10/22/2018 | PhaseBio Pharmaceuticals Inc | PHAS | Conversion | Common Stock | 2.4M | $0.00 | $0 | By Zeneca, Inc. | 10/22/2018 |
| 10/22/2018 | PhaseBio Pharmaceuticals Inc | PHAS | Purchase | Common Stock | 600k | $5.00 | $3M | By Zeneca, Inc. | 10/22/2018 |
| 10/22/2018 | PhaseBio Pharmaceuticals Inc | PHAS | Exercise (in-the-money or at-the-money) | Warrants to Purchase Series C-1 Preferred Stock | 113.9k | $0.12 | $13.7k | By Zeneca, Inc. | 10/22/2018 |
| 10/22/2018 | PhaseBio Pharmaceuticals Inc | PHAS | Exercise (in-the-money or at-the-money) | Series C-1 Preferred Stock | 113.9k | $0.12 | $13.7k | By Zeneca, Inc. | 10/22/2018 |
| 10/22/2018 | PhaseBio Pharmaceuticals Inc | PHAS | Sale | Series C-1 Preferred Stock | 2.7k | $5.00 | $13.7k | By Zeneca, Inc. | 10/22/2018 |
| 10/22/2018 | PhaseBio Pharmaceuticals Inc | PHAS | Conversion | Series C-1 Preferred Stock | 1.7M | $0.00 | $0 | By Zeneca, Inc. | 10/22/2018 |
| 10/22/2018 | PhaseBio Pharmaceuticals Inc | PHAS | Conversion | Series D Preferred Stock | 740.3k | $0.00 | $0 | By Zeneca, Inc. | 10/22/2018 |
| 09/28/2018 | Entasis Therapeutics Holdings Inc. | ETTX | Conversion | Series A Preferred Stock | 33.5M | $0.00 | $0 | See Footnote | 09/28/2018 |
| 09/28/2018 | Entasis Therapeutics Holdings Inc. | ETTX | Purchase | Common Stock | 246.7k | $15.00 | $3.7M | See Footnote | 09/28/2018 |
| 09/28/2018 | Entasis Therapeutics Holdings Inc. | ETTX | Conversion | Common Stock | 1.9M | $0.00 | $0 | See Footnote | 09/28/2018 |
| 12/01/2017 | ALBIREO PHARMA, INC. | ALBO | Sale | Common Stock, $0.01 par value per share | 500k | $21.40 | $10.7M | Held by AstraZeneca AB | 12/01/2017 |
| 11/12/2014 | Regulus Therapeutics Inc. | RGLS | Sale | COMMON STOCK | 2M | $17.00 | $34M | See footnote | 11/12/2014 |